TargetMol

Afatinib Dimaleate

Product Code:
 
TAR-T1773
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1773-5mg5mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1773-10mg10mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1773-1mL1 mL * 10 mM (in DMSO)£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1773-25mg25mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1773-100mg100mg£186.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1773-200mg200mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
CAS:
850140-73-7
Formula:
C32H33ClFN5O11
Molecular Weight:
718.09
Pathway:
Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors; Autophagy
Purity:
0.9966
SMILES:
OC(=O)C=C/C(O)=O.OC(=O)C=C/C(O)=O.CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
Target:
EGFR; HER; Autophagy

References

1. D Li, et al. Oncogene. 2008, 27(34):4702-4711. 2. Wang XK, et al. Cancer Res. 2014, 74(16):4431-4445. 3. Gurtner K, et al. Radiat Oncol. 2014, 9:261. 4. Schwab CL, et al. Br J Cancer. 2014, 111(9):1750-1756. 5. Janjiqian YY, et al. J Nucl Med. 2013, 54(6):936-943. 6. Li C, Sun Y D, Yu G Y, et al. Integrated Omics of Metastatic Colorectal Cancer[J]. Cancer Cell. 2020, 38(5): 734-747. e9